Zombie NIR™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye, Dead, Apoptosis
Ave. Rating
Submit a Review
Product Citations
publications
Zombie_NIR_Antibody_FC_062413
One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
  • Zombie_NIR_Antibody_FC_062413
    One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
See Zombie NIR™ spectral data
Cat # Size Price Quantity Check Availability Save
423105 100 tests £61
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423106 500 tests £230
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie NIR™ is an amine reactive fluorescent dye that is non-permeant to live cells, but permeant to the cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie NIR™ is a polar water soluble dye, providing red fluorescence, making it suitable for multi-color detection.

Product Details
Technical Data Sheet (pdf)

Product Details

Preparation
Zombie NIR™ Fixable Viability kit is composed of lyophilized Zombie NIR™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye until fully dissolved. 100 tests = 1 vial of Zombie NIR™ + DMSO, 500 tests = 5 vials of Zombie NIR™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie NIR™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

Excitation Laser
Red Laser (633 nm)
Application Notes

Zombie NIR™ dye is excited by the red laser and has fluorescence emission maximum at 746 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie NIR™ dye has similar emission to APC/Cyanine7.

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrifuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie NIR™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µL Zombie NIR™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µL for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  5. Incubate the cells at room temperature (or 4°C), in the dark, for 15-30 minutes.
  6. Wash one time with 2 mL BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

No-wash Sequential Staining Protocol:

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully  dissolved
  3. Determine the total µL volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µL. Subtract that antibody volume from the 100 µL total staining volume intended for the assay. In the remaining volume, dilute Zombie NIR™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µL of antibody cocktail for a 100 µL total staining volume, use 80 µL of Zombie NIR™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie NIR™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  4. Incubate for 10-15 minutes at RT (or 4°C), protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.
    • Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie NIR™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie NIR™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie NIR™.
Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Application References

(PubMed link indicates BioLegend citation)
  1. McMaster SR, et al. 2015. PLoS One. 10:115725. PubMed
  2. Prado-Garcia H, et al. 2015. Anticancer Res.35:1529. PubMed
  3. Rodriguez-Rodriguez N, et al. 2015. J Immunol. 194:4207. PubMed
  4. Flies DB, et al. 2015. J Immunol. 194:5294. PubMed
Product Citations
  1. Headley M, et al. 2016. Nature. 531:513-517. PubMed
  2. Wang L, et al. 2020. Front Cell Dev Biol. 0.745138889. PubMed
  3. Iyer S, et al. 2021. Cancer Discov. 0.725. PubMed
  4. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  5. Rad S M AH, et al. 2020. PLoS One. 15:e0232915. PubMed
  6. Pandey SP, et al. 2022. Cell Host Microbe. 30:1003. PubMed
  7. Knelson EH, et al. 2022. Cancer Immunol Res. 10:947. PubMed
  8. Sun Y, et al. 2022. STAR Protoc. 3:101479. PubMed
  9. Edwards KJ, et al. 2022. Cancer Immunol Res. 10:1084. PubMed
  10. Park G, et al. 2023. Photochem Photobiol. 99:850. PubMed
  11. Zhao Y, et al. 2022. J Neurosci. . PubMed
  12. Lutz EA, et al. 2022. Proc Natl Acad Sci U S A. 119:e2205983119. PubMed
  13. Sauter M, et al. 2022. STAR Protoc. 3:101664. PubMed
  14. Terminel MN, et al. 2022. BMC Neurosci. 23:58. PubMed
  15. Tan GMY, et al. 2022. Cancers (Basel). 14:. PubMed
  16. Prochazka L, et al. 2022. Mol Syst Biol. 18:e10886. PubMed
  17. Egli J, et al. 2022. MAbs. 14:2143009. PubMed
  18. Han X, et al. 2022. Nutrients. 14:. PubMed
  19. Li Y, et al. 2023. Adv Mater. 35:e2208923. PubMed
  20. Schönberger K, et al. 2023. Anal Chem. 95:4325. PubMed
  21. Tschanz F, et al. 2021. Cancer Res Commun. 1:164. PubMed
  22. Liu HJ, et al. 2023. Nat Commun. 14:1214. PubMed
  23. Tan J, et al. 2023. Acta Pharm Sin B. 13:632. PubMed
  24. Muri J, et al. 2023. Nat Immunol. 24:604. PubMed
  25. Zhou P, et al. 2023. Immunity. 56:669. PubMed
  26. Ananya A, et al. 2023. Immun Ageing. 20:10. PubMed
  27. Pasqual G, et al. 2023. Methods Mol Biol. 2618:71. PubMed
  28. Luo X, et al. 2023. Methods Mol Biol. 2618:133. PubMed
  29. Jiang X, et al. 2023. J Clin Invest. 133:. PubMed
  30. Pankhurst TE, et al. 2023. Cell Rep. 42:112310. PubMed
  31. Martins Nascentes Melo L, et al. 2023. J Immunother Cancer. 11:. PubMed
  32. Zhang YN, et al. 2023. Nat Commun. 14:1985. PubMed
  33. Onyshchenko K, et al. 2023. Nat Commun. 14:2087. PubMed
  34. Xu Z, et al. 2023. Cancers (Basel). 15:. PubMed
  35. Liu L, et al. 2023. J Exp Clin Cancer Res. 42:85. PubMed
  36. Glasner A, et al. 2023. Nat Immunol. 24:1020. PubMed
  37. Sugita M, et al. 2023. Cell Death Dis. 14:305. PubMed
  38. Lee K, et al. 2023. JCI Insight. 8:. PubMed
  39. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  40. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  41. Villalba N, et al. 2023. J Neuroinflammation. 20:127. PubMed
  42. Meckler JF, et al. 2023. Cancer Immunol Immunother. . PubMed
  43. Imai H, et al. 2023. iScience. 26:106822. PubMed
  44. Braun DJ, et al. 2023. PLoS One. 18:e0286495. PubMed
  45. Zhang TR, et al. 2023. Pharmaceuticals (Basel). 16:. PubMed
  46. Li JD, et al. 2023. Front Immunol. 14:1186393. PubMed
  47. Wu L, et al. 2023. Cell Res. . PubMed
  48. Cansever D, et al. 2023. Nat Immunol. . PubMed
  49. Liu X, et al. 2023. J Neuroinflammation. 20:144. PubMed
  50. Hall, J. M., Caution, K. J., et al. 2025. Emerg Microbes Infect. 14(1),2547732. PubMed
  51. Wiese, M., Pessoa Rodrigues, C., et al. 2025. Life Sci Alliance. 8(12),0. PubMed
  52. Chen, F., Bradbury, M. S., et al. 2025. J Nanobiotechnology. 23(1),627. PubMed
  53. Liu, F., Tarannum, M., et al. 2025. Nat Commun. 16(1),8809. PubMed
  54. Jouve, C., Ruiz-Velasco, A., et al. 2025. Commun Biol. 8(1),1445. PubMed
  55. Ogunlusi, O., Sarkar, M., et al. 2025. Oncogene. 44(46),4491-4504. PubMed
  56. Yang, S., Cui, Y. H., et al. 2025. Nat Commun. 16(1),9946. PubMed
  57. Pascoe, R. D., Gubser, C., et al. 2025. EBioMedicine. 122(0),106004. PubMed
  58. Underwood, M. T., Devarapalli, V., et al. 2025. Noncoding RNA. 11(6),0. PubMed
  59. Yates, J. G. E., Chan, L., et al. 2025. Mol Ther Oncol. 33(4),201076. PubMed
  60. Weidling, H., Motta, E., et al. 2025. Front Immunol. 16(0),1645062. PubMed
  61. Jiang, X., Wang, M., et al. 2025. Mater Today Bio. 35(0),102593. PubMed
  62. Du, Z., Wan, P., et al. 2025. Nat Commun. 16(1),11168. PubMed
  63. Kim MY, et al. 2021. JCI Insight. 6:. PubMed
  64. Martínez-Vélez N, et al. 2022. Mol Cancer Ther. 21:471. PubMed
  65. Baratchart E, et al. 2022. PLoS Comput Biol. 18:e1009839. PubMed
  66. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  67. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  68. Hsu MA, et al. 2022. Cancer Immunol Immunother. :. PubMed
  69. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  70. Wu R, et al. 2022. J Dermatol. 49:432. PubMed
  71. Wang W, et al. 2022. Dev Cell. 57:228. PubMed
  72. Chaurio RA, et al. 2022. Immunity. 55:115. PubMed
  73. Cautivo KM, et al. 2022. Immunity. 55:254. PubMed
  74. Kuloglu ZE, et al. 2022. Allergy. 77:2459. PubMed
  75. Bayley R, et al. 2022. Mol Cell. 82:1924. PubMed
  76. Rodriguez-Tirado C, et al. 2022. Cancer Res. 82:2313. PubMed
  77. Tang Q, et al. 2022. Mol Ther. 30:2709. PubMed
  78. Gideon HP, et al. 2022. Immunity. 55:827. PubMed
  79. Zhang Y, et al. 2022. Nat Med. 28:1421. PubMed
  80. Sudmeier LJ, et al. 2022. Cell Rep Med. 3:100620. PubMed
  81. Naseem MU, et al. 2022. J Gen Physiol. 154: . PubMed
  82. Vukovic N, et al. 2022. J Biol Chem. 298:102153. PubMed
  83. Berger G, et al. 2022. Proc Natl Acad Sci U S A. 119:e2111003119. PubMed
  84. Hsieh T, et al. 2022. Front Immunol. 13:901030. PubMed
  85. Werder RB, et al. 2022. Sci Adv. 8:eabo6566. PubMed
  86. Zhu Y, et al. 2022. Immunology. 167:576. PubMed
  87. Ostendorf BN, et al. 2022. Nature. 611:346. PubMed
  88. Wang Z, et al. 2022. J Exp Med. 219: . PubMed
  89. Naranjo S, et al. 2022. Genes Dev. 36:936. PubMed
  90. Buckner CM, et al. 2022. Cell. 185:4333. PubMed
  91. VanDyke D, et al. 2022. Cell Rep. 41:111478. PubMed
  92. Wang W, et al. 2022. Cell Rep. 41:111582. PubMed
  93. Ogishi M, et al. 2023. J Exp Med. 220: . PubMed
  94. Zhu H, et al. 2023. Clin Transl Radiat Oncol. 38:138. PubMed
  95. Schaefer-Babajew D, et al. 2023. Nature. 613:735. PubMed
  96. Edwards SC, et al. 2023. J Exp Med. 220: . PubMed
  97. Naylor G, et al. 2022. Cancers (Basel). 14: . PubMed
  98. Ronning KE, et al. 2022. J Neuroinflammation. 19:299. PubMed
  99. Pleuger C, et al. 2022. Elife. 11: . PubMed
  100. Dutt TS, et al. 2022. Cell Rep. 41:111783. PubMed
  101. Xu Q, et al. 2023. Nat Immunol. 24:186. PubMed
  102. Hägglöf T, et al. 2023. Cell. 186:147. PubMed
  103. Schepers M, et al. 2023. Brain Behav Immun. 109:1. PubMed
  104. Gauthier L, et al. 2023. Nat Biotechnol. :. PubMed
  105. Ali LR, et al. 2023. J Exp Med. 220: . PubMed
  106. Zhou H, et al. 2023. Front Immunol. 13:1059687. PubMed
  107. Vyas M, et al. 2023. Front Immunol. 13:1098445. PubMed
  108. Rosain J, et al. 2023. Cell. 186:621. PubMed
  109. Ernst MPT, et al. 2023. Hemasphere. 7:e824. PubMed
  110. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
  111. Dragan M, et al. 2022. J Invest Dermatol. 142:583. PubMed
  112. Parida PK, et al. 2022. Cell Metab. 34:90. PubMed
  113. Ma Y, et al. 2022. Am J Physiol Heart Circ Physiol. 322:H622. PubMed
  114. Salmon AJ, et al. 2022. Cancer Immunol Res. 10:597. PubMed
  115. Nelson LJ, et al. 2022. Cell Cycle. 21:1103. PubMed
  116. Kania AK, et al. 2022. J Immunol. 208:1873. PubMed
  117. Xu Y, et al. 2022. Bio Protoc. 12:e4354. PubMed
  118. McCafferty S, et al. 2022. Mol Ther. 30:2968. PubMed
  119. Liu Y, et al. 2022. Signal Transduct Target Ther. 7:347. PubMed
  120. Sheikh BN, et al. 2020. Nat Cell Biol. 22:828. PubMed
  121. Pathak JL, et al. 2021. Front Cell Dev Biol. 628139:9. PubMed
  122. Jiang C, et al. 2020. Int J Biol Sci. 2.802083333. PubMed
  123. Qiu J, et al. 2020. Cell Rep. 33:108465. PubMed
  124. Sagami S, et al. 2017. PLoS One. 10.1371/journal.pone.0169681. PubMed
  125. Lentucci C, et al. 2017. J Biol Chem. 292:2754-2772. PubMed
  126. Montes de Oca M, et al. 2016. Cell Rep. 17:399-412. PubMed
  127. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  128. Gibb D, et al. 2016. EBioMedicine. 9: 77-86. PubMed
  129. Kallemeijn WW, et al. 2019. Cell Chem Biol. 26:892. PubMed
  130. Kollareddy M, et al. 2017. Cancer Lett. 10.1016/j.canlet.2017.05.027. PubMed
  131. Ajoge HO, et al. 2022. Viruses. 14:. PubMed
  132. Tan L, et al. 2022. Biochem Biophys Rep. 32:101351. PubMed
  133. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  134. He C, et al. 2022. Sci Adv. 8:eabm4552. PubMed
  135. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  136. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  137. Landry LG, et al. 2021. Bio Protoc. 11:e3883. PubMed
  138. Barros-Martins J, et al. 2021. Nat Med. 27:1525. PubMed
  139. Nordengrün M, et al. 2021. Front Immunol. 12:651060. PubMed
  140. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  141. Ma Q, et al. 2021. Clin Transl Immunology. 10:e1300. PubMed
  142. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  143. Jimenez-Duran G, et al. 2020. EBioMedicine. 61:103039. PubMed
  144. Li JY, et al. 2020. J Clin Invest. 130:1767. PubMed
  145. Kilens S, et al. 2018. Nat Commun. 9:360. PubMed
  146. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  147. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  148. Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed
  149. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  150. Sauter M, et al. 2022. iScience. 25:103677. PubMed
  151. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  152. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  153. Sneller MC, et al. 2022. Nature. 606:375. PubMed
  154. Hamminger P, et al. 2021. J Autoimmun. 119:102610. PubMed
  155. Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
  156. Schalbetter SM, et al. 2022. Sci Adv. 8:eabi6672. PubMed
  157. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  158. Agudelo M, et al. 2021. J Exp Med. :218. PubMed
  159. Gaebler C, et al. 2021. Nature. 639:591. PubMed
  160. Olingy C, et al. 2017. Sci Rep. 10.1038/s41598-017-00477-1. PubMed
  161. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
  162. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  163. Liu HJ, et al. 2018. JCI Insight. 3. PubMed
  164. Zou L, et al. 2022. Brain Behav Immun. 100:10. PubMed
  165. Son ET, et al. 2021. J Clin Invest. 131:. PubMed
  166. Majstrowicz K, et al. 2021. J Cell Sci. 134:. PubMed
  167. Daniel S, et al. 2021. Infect Immun. 89:e0016521. PubMed
  168. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  169. Michaud D, et al. 2022. Front Immunol. 12:745873. PubMed
  170. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  171. Watters JM, et al. 2021. Biochem Biophys Res Commun. 534:773. PubMed
  172. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  173. Bouffi C, et al. 2015. J Immunol. 195: 2683-2695. PubMed
  174. Higuchi T, et al. 2015. Cancer Immunol Res. 3: 1257 - 1268. PubMed
  175. Woodruff MC, et al. 2020. Nat Immunol. 1.920833333. PubMed
  176. Xu AQ, et al. 2020. Elife. 9:00. PubMed
  177. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  178. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  179. Guarnaccia AD, et al. 2021. Cell Rep. 108636:34. PubMed
  180. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  181. Verma M, et al. 2018. Cell Stem Cell. 23:530. PubMed
  182. Weisberg SP, et al. 2020. Cell Reports. 29(12):3916-3932.e5.. PubMed
  183. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  184. Hering L, et al. 2021. Int J Mol Sci. 22:. PubMed
  185. Halim L, et al. 2022. Front Immunol. 13:836549. PubMed
  186. Hemkemeyer SA, et al. 2020. J Biol Chem. 296:100136. PubMed
  187. Massafra V, et al. 2021. J Immunol. 207:493. PubMed
  188. Agudelo M, et al. 2022. J Exp Med. 219:. PubMed
  189. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  190. Woodruff MC, et al. 2022. Nature. :. PubMed
  191. Patricio DO, et al. 2022. Front Immunol. 13:1042463. PubMed
  192. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  193. Akiyama H, et al. 2020. J Virol. . PubMed
  194. Sperber HS, et al. 2020. FASEB J. 14615:34. PubMed
  195. Moreau GB, et al. 2020. Am J Trop Med Hyg. 103:1215. PubMed
  196. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  197. Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed
  198. Retamal‐Díaz A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01523. PubMed
  199. Wlodarska M et al. 2017. Cell host & microbe. 22(1):25-37 . PubMed
  200. Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed
  201. Mahmoud W, et al. 2021. Cell Tissue Res. Online ahead of print. PubMed
  202. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  203. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  204. Michaud D, et al. 2020. Cytokine. 125:154817. PubMed
  205. Simonneau M, et al. 2018. Oncotarget. 9:36457. PubMed
  206. Koizumi SI, et al. 2018. Nat Commun. 9:5344. PubMed
  207. Miller EB, et al. 2021. J Neuroinflammation. 18:235. PubMed
  208. Mills C, et al. 2022. Cells. 11:. PubMed
  209. Pettinato G, et al. 2021. Sci Adv. 7:. PubMed
  210. Godoy-Pacheco A, et al. 2022. Oncol Lett. 24:288. PubMed
  211. Rao X, et al. 2022. Cell Death Dis. 13:891. PubMed
  212. Sato R, et al. 2020. Int Immunol. 499:32. PubMed
  213. Aregger M, et al. 2020. Nat Metab. 0.429861111. PubMed
  214. Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed
  215. PRADO-GARCIA H, et al. 2015. Anticancer Res. 35:1529. PubMed
  216. Lisk C, et al. 2020. Front Immunol. 1.329166667. PubMed
  217. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  218. Casella G, et al. 2017. Sci Rep. . 10.1038/s41598-017-16702-w. PubMed
  219. Adamik J, et al. 2022. Nat Commun. 13:5184. PubMed
  220. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  221. Zhang Z, et al. 2021. Acta Pharm Sin B. 11:1965. PubMed
  222. Mahadevan NR, et al. 2021. Cancer Discov. 11:1952. PubMed
  223. Alansary M, et al. 2021. Dent Traumatol. 37:90. PubMed
  224. Le X, et al. 2021. J Thorac Oncol. 16:583. PubMed
  225. Song D, et al. 2021. Sci Rep. 11:22966. PubMed
  226. Aires V, et al. 2021. Front Immunol. 12:684430. PubMed
  227. Choi JE, et al. 2021. Nat Metab. 3:182. PubMed
  228. Ajina R, et al. 2021. Cancer Immunol Res. 9:386. PubMed
  229. Steinbach K, et al. 2016. J Exp Med. 213: 1571 - 1587. PubMed
  230. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  231. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  232. Wang Z, et al. 2021. bioRxiv. . PubMed
  233. Wang K, et al. 2018. Medicine (Baltimore). 97:e0710. PubMed
  234. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  235. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  236. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  237. Thyrsted J, et al. 2021. iScience. 24:103300. PubMed
  238. Basu A, et al. 2021. Cancer Immunol Res. Online ahead of print. PubMed
  239. Viant C, et al. 2021. J Exp Med. 218:. PubMed
  240. Nakajima T, et al. 2021. J Exp Med. 218:. PubMed
  241. Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed
  242. Ferrer-Font L, et al. 2021. Curr Protoc. 1:e222. PubMed
  243. Li Y, et al. 2022. J Neuroinflammation. 19:261. PubMed
  244. Woodruff M, et al. 2020. medRxiv. . PubMed
  245. McHugh D, et al. 2020. Life Sci Alliance. 3:00. PubMed
  246. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
  247. English KG, et al. 2022. Biomedicines. 10:. PubMed
  248. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  249. Stinson WA, et al. 2022. JCI Insight. 7:. PubMed
  250. Kim S, et al. 2022. Redox Biol. 54:102347. PubMed
  251. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  252. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  253. Christopher GA, et al. 2021. Biomolecules. 12:. PubMed
  254. Cho A, et al. 2021. Nature. Online ahead of print. PubMed
  255. Clapes T, et al. 2021. Nat Cell Biol. 23:704. PubMed
  256. Johnson AM, et al. 2020. J Immunol. 204:2295. PubMed
  257. Thompson EA, et al. 2021. Cell Rep. 108863:34. PubMed
  258. Espinoza J, et al. 2017. Oxidative Medicine and Cellular Longevity. 10.1155/2017/6781872. PubMed
  259. Pinder C, et al. 2017. J Immunol. 10.4049/jimmunol.1701253. PubMed
  260. Popay TM, et al. 2021. Elife. 10: . PubMed
  261. Wan G, et al. 2021. Sci Rep. 11:22121. PubMed
  262. Hills LB, et al. 2021. J Immunol. 206:89. PubMed
  263. Kuhn JA, et al. 2021. Elife. 10:. PubMed
  264. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  265. Xu Y, et al. 2021. Front Immunol. 12:666991. PubMed
  266. Zhang H, et al. 2021. Cell Rep. 36:109708. PubMed
  267. Zhu S, et al. 2022. J Oncol. 2022:8724933. PubMed
  268. Liu Y, et al. 2022. Front Oncol. 12:1037934. PubMed
  269. Scharer CD, et al. 2020. Nat Commun. 3989:11. PubMed
  270. Rodríguez-Rodríguez N, et al. 2015. J Immunol. 194:4207. PubMed
  271. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  272. Ito Y, et al. 2018. Cell. 174:636. PubMed
  273. Lim JME, et al. 2022. Cell Rep Med. 3:100793. PubMed
  274. Vanekova L, et al. 2022. Methods Protoc. 5:. PubMed
  275. Elias G, et al. 2022. Elife. 11:. PubMed
  276. Cohen CA, et al. 2021. Nat Commun. 12:4678. PubMed
  277. Ruibal P, et al. 2016. Nature. 533: 100-104. PubMed
  278. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  279. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  280. Hemkemeyer SA, et al. 2020. J Biol Chem. . PubMed
  281. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  282. Akuffo AA, et al. 2018. J Biol Chem. 293:6187. PubMed
  283. Morganti JM, et al. 2019. J Neuroinflammation. 16:98. PubMed
  284. McGinnis CS, et al. 2019. Nat Methods. 1.096527778. PubMed
  285. Günther T, et al. 2019. PLoS Pathog. 15:e1007838. PubMed
  286. Fujimoto N, et al. 2020. PLoS Biol. 18:e3000704. PubMed
  287. Meyrath M, et al. 2020. Nat Commun. 2.564583333. PubMed
  288. Luo G, et al. 2021. Sci Rep. 11:7841. PubMed
  289. Braun DA, et al. 2021. Cancer Cell. 39:632. PubMed
  290. Cui Z, et al. 2021. Cell Death Dis. 12:775. PubMed
  291. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  292. Valestrand L, et al. 2022. Am J Pathol. . PubMed
  293. Espinal A, et al. 2022. Int J Mol Sci. 23:. PubMed
  294. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  295. Jalloh S, et al. 2022. PLoS Pathog. 18:e1010479. PubMed
  296. Soley BDS, et al. 2020. Br J Pharmacol. 177:3535. PubMed
  297. Lo CH, et al. 2021. Sci Rep. 6055:11. PubMed
  298. Salazar Y, et al. 2020. J Clin Invest. 130:3560. PubMed
  299. Bhattacharya P, et al. 2020. Elife. 9:00. PubMed
  300. Grubiši? V, et al. 2020. Cell Rep. 32:108100. PubMed
  301. Shim K, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.023. PubMed
  302. Tomić A, et al. 2016. PLoS Pathog. 12:e1006015. PubMed
  303. Filiano A, et al. 2016. Nature. 535:425-429. PubMed
  304. Armbruster N, et al. 2016. J Immunol. 196: 1284 - 1292. PubMed
  305. Ramachandran P, et al. 2019. Nature. 575:512. PubMed
  306. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  307. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  308. Waight JD, et al. 2018. Cancer Cell. 33:1033. PubMed
  309. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  310. Qadir AS, et al. 2021. iScience. 24:103348. PubMed
  311. Lozano-Ojalvo D, et al. 2021. Cell Rep. 36:109570. PubMed
  312. Dieterle ME, et al. 2021. Elife. 10:. PubMed
  313. Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed
  314. Clement CC, et al. 2021. Immunity. 54:721. PubMed
  315. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
  316. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  317. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  318. Noort RJ, et al. 2021. Front Cell Dev Biol. 9:659397. PubMed
  319. Cloarec R, et al. 2016. PLoS One. 11: 0160176. PubMed
  320. Rouleau N, et al. 2020. Immunohorizons. 0.695833333. PubMed
  321. Rizvi F, et al. 2021. Nat Commun. 0.925694444. PubMed
  322. Herland A, et al. 2020. Nat Biomed Eng. 421:4. PubMed
  323. Oherle K, et al. 2020. Immunity. 275:52. PubMed
  324. Zhang Y, et al. 2018. Front Microbiol. 9:2967. PubMed
  325. Grajchen E, et al. 2020. J Neuroinflammation. 0.863888889. PubMed
  326. Wang Z, et al. 2021. Nature. 592:616. PubMed
  327. Ramos MIP, et al. 2021. Elife. 10:. PubMed
  328. Su Y, et al. 2021. Clin Cancer Res. :clincanres.2241.2021. PubMed
  329. Dudek M, et al. 2021. Nature. 592:444. PubMed
  330. Jacobsen H, et al. 2021. Nat Commun. 12:4957. PubMed
  331. Cillo AR, et al. 2021. Cell Rep Med. 2:100476. PubMed
  332. Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed
  333. Wang Z, et al. 2022. J Exp Med. 219:. PubMed
  334. He Y, et al. 2022. Cells. 11:. PubMed
  335. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  336. Luo L, et al. 2021. J Neuroinflammation. 18:27. PubMed
  337. Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed
  338. McMaster S, et al. 2015. PLoS One. 10:115725. PubMed
  339. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  340. Manuszak C, et al. 2020. J Biol Methods. 7:e131. PubMed
  341. McKenzie MD, et al. 2019. Cell Stem Cell. 25:258. PubMed
  342. Zischke J, et al. 2017. PLoS Pathogens. 13(6):e1006454. PubMed
  343. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  344. Tang JS, et al. 2022. Front Immunol. 13:946713. PubMed
  345. Wang Z, et al. 2021. Nature. 595:426. PubMed
  346. Mumby MJ, et al. 2021. J Virol. 95:e0058821. PubMed
  347. Chou TW, et al. 2021. Cell Death Dis. 12:756. PubMed
  348. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  349. Hobbs BE, et al. 2021. Pathogens. 10:. PubMed
  350. Fan ZP, et al. 2021. Front Immunol. 12:743354. PubMed
  351. Lien TS, et al. 2021. Front Immunol. 12:618577. PubMed
  352. Phan TS, et al. 2021. Sci Adv. 7:. PubMed
  353. Flies D, et al. 2015. J Immunol. 194:5294. PubMed
  354. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  355. Korin B, et al. 2020. Sleep. :43. PubMed
  356. Santopaolo M, et al. 2021. Front Immunol. 609406:12. PubMed
  357. Daniels M, et al. 2017. Sci Rep.. 10.1038/s41598-017-17387-x. PubMed
  358. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  359. Donlan AN, et al. 2021. JCI Insight. 6: . PubMed
  360. Lisk C, et al. 2021. Front Immunol. 12:624197. PubMed
  361. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  362. Denoth-Lippuner A, et al. 2021. Cell Stem Cell. 28:2020. PubMed
  363. Zhang Y, et al. 2022. Mater Today Bio. 15:100317. PubMed
  364. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  365. Madsen CS, et al. 2022. Commun Biol. 5:888. PubMed
  366. Maas RR, et al. 2021. Nat Protoc. 16:4692. PubMed
  367. Lee HY, et al. 2021. Curr Protoc. 1:e272. PubMed
  368. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
  369. Chou DB, et al. 2022. Nat Commun. 13:6021. PubMed
  370. Gaebler C, et al. 2020. bioRxiv. . PubMed
  371. Shimada BK, et al. 2020. Immunohorizons. 0.55625. PubMed
  372. Jeffery H, et al. 2017. Clin Exp Immunol. 10.1111/cei.12940. PubMed
  373. Hosking M, Flynn C, Whitton J 2016. PLoS Pathog. 12: 1005861. PubMed
  374. Bryan AF, et al. 2020. Nucleic Acids Res. 48:2924. PubMed
  375. Sontheimer-Phelps A, et al. 2019. Cell Mol Gastroenterol Hepatol. 9:507. PubMed
  376. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  377. Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed
  378. Chakraborty A, et al. 2022. Methods Mol Biol. 2442:565. PubMed
  379. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  380. Kiesel VA, et al. 2022. Front Oncol. 12:767479. PubMed
  381. Gutierrez-Prat N, et al. 2022. Life Sci Alliance. 5:. PubMed
  382. Viant C, et al. 2020. Cell. 183:1298. PubMed
  383. Heckler M, et al. 2021. Cancer Discov. Online ahead of prin. PubMed
  384. Maller O, et al. 2020. Nat Mater. 20:548. PubMed
  385. Chou DB, et al. 2020. Nat Biomed Eng. 0.440277778. PubMed
  386. Wachowska M, et al. 2020. Cancer Immunol Immunother. 69:1101. PubMed
  387. Gangoso E, et al. 2021. Cell. 184:2454. PubMed
  388. Sibler E, et al. 2021. Cells. 10:. PubMed
  389. Qin J, et al. 2020. Cancer Immunol Res. 8:1426. PubMed
  390. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  391. Kastenschmidt JM, et al. 2021. Cell Rep. 35:108997. PubMed
  392. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  393. Sibler E, et al. 2022. Cancers (Basel). 14:. PubMed
  394. Spath S, et al. 2022. iScience. 25:104998. PubMed
  395. Farrand K, et al. 2022. Curr Protoc. 2:e482. PubMed
  396. Clutton G, et al. 2016. Sci Rep. 6:30749. PubMed
  397. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  398. Muchowicz A, et al. 2017. Eur J Cancer. 10.1016/j.ejca.2017.06.004. PubMed
  399. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  400. Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed
  401. Zhang N, et al. 2022. Front Immunol. 13:926368. PubMed
  402. Cho A, et al. 2022. J Exp Med. 219:. PubMed
  403. Celias DP, et al. 2022. STAR Protoc. 3:101464. PubMed
  404. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  405. Zhou P, et al. 2022. Sci Transl Med. :eabi9215. PubMed
  406. Sauler M, et al. 2022. Nat Commun. 13:494. PubMed
  407. Guarnaccia AD, et al. 2021. STAR Protoc. 2:101000. PubMed
  408. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
  409. Gamradt S, et al. 2021. iScience. 24:103312. PubMed
  410. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
  411. Goddery EN, et al. 2021. Front Immunol. 12:726421. PubMed
  412. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  413. Dar HH, et al. 2021. Redox Biol. 45:102045. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Go To Top Version: 7    Revision Date: 12/18/2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account